CFB and breast cancer: By targeting distinct regulators of the ROCK/MLCK/myosin pathway, cholestatic compounds with diverse chemical structures and therapeutic properties can induce alterations in the contractile movements of BC and impairments in the secretion of BA (Fig. 11).